Bioprojet

Sun Pharma Advanced Research Company Limited

Bioproject

Philippe Robert

Jean-Charles Schwartz

Jeanne-Marie Lecomte

Marc Capet

Nicolas Levoin

Xavier Ligneau

Isabelle Berrebi-Bertrand

Thierry Calmels

Olivier Labeeuw

Xavier Billot

Stéphane Krief

Denis Danvy

Rajamannar Thennati

Olivia Poupardin-Olivier

Jayraj Dilipbhai Aradhye

Bhavesh Mohanbhai Panchal

Ranjan Kumar Pal

Biswajit Samanta

Muthukumaran Natarajan Pillai

Isabelle Bertrand

Marc Maury

Japan Nitinkumar Desai

Sandeep Pankajbhai Pathak

Marcel Morvan

Kaushik Dhanjubhai Prajapati

Dijixa Chandubhai Rana

Jean-Stëphane Julien

Jignesh Kantilal Jivani

Rajamannar c/o Sun Pharma Advanced Research Centre Thennati

Biswajit c/o Sun Pharma Advanced Research Centre Samanta

Ranjan Kumar c/o Sun Pharma Advanced Research Centre Pal

Isabelle Berrebi Bertrand

Jean-Stéphane Julien

Jayraj D Aradhye

Bhavesh M Panchal

Jean-Stephane Julien

The present application concerns novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands.

Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands

Novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands are disclosed.

The present invention relates to a new formulation of an enkephalinase inhibitor, such as racecadotril or dexecadotril, the process for the preparation thereof, and the use thereof in the treatment of diarrhea.

Form of administration of enkephalinase inhibitor

The present invention relates to novel compounds acting as agonists at S1P (sphingosine-1-phosphate) receptors, compositions containing these compounds, use of these compounds in medicine and their process of preparation. 

Piperidinyl monocarboxylic acids as S1P1 receptor agonists

The present patent application concerns new ligands of the H4-receptor, their process of preparation and their therapeutic use.

6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands

The present invention concerns novel (aza)benzhydryl ether derivatives which exhibit H4-receptor binding activity. The present invention also concerns their process of preparation and their therapeutical uses.

(Aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications

Benzazole derivatives as histamine H4 receptor ligands

The present invention relates to new compounds of formula (I) possessing agonistic activity at sphingosine-1-phosphate (S1P) receptors, their process of preparation and their use as immunosuppressive agents. The invention is also directed to pharmaceutical compositions containing these compounds and use of these compounds for treatment/prevention of immune mediated diseases and conditions or inflammatory diseases and conditions.

Dicarboxylic acid derivatives as S1P1 receptor agonists

The present patent application concerns new ligands of the H4-receptor of formula (I), their process of preparation and their therapeutic use. 

The invention relates to compounds of the general formula (I): to the process for preparing them, and to the use thereof as a therapeutic agent. 

[object Object]

The present patent application concerns compounds of formula (I) with R1 and R2 taken together with the nitrogen atom to which they are attached, form a mono or bicyclic saturated nitrogen-containing ring; their preparation and their use as a H3 receptor ligand for treating e.g. CNS disorders like Alzheimer's disease.

Histamine H3-receptor ligands and their therapeutic applications

The present patent application concerns new compounds of formula (I) with Rand Rtaken together with the nitrogen atom to which they are attached, form a saturated nitrogen-containing ring, A is a saturated C1-4 alkylene and B a C3-4 alkylene or alkenylene chain; their preparation and their use as a H3 receptor ligand for treating e.g. CNS disorders like Alzheimer's disease. 

The invention relates to compounds of the general formula (I): to the process for preparing them, and to the use thereof as a therapeutic agent having the property of being selective ligands for the dopamine D3 receptor. These selective D3 ligands are useful as medicines in neuropsychiatry, in particular in the treatment of psychotic or depressive states, or in the treatment of motor disorders, such as dyskinesia or essential tremor. They are furthermore useful in the treatment of dependency on nicotine, cocaine, alcohol, opioids and for facilitating withdrawal in drug-dependent individuals.

Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents

Growing community of inventors

Pace, France

Philippe Robert